Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate

Details Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate

1995-04-12

1998-06-30

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 530317, 530324, 530325, 530326, 530327, 530328, 530329, A61K 3808, A61K 3810, A61K 3812, A61K 3816

Patent

active

057734127

ABSTRACT:
The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

REFERENCES:
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5041380 (1991-08-01), Ruoslahti et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5227469 (1993-07-01), Lazarus et al.
Aumailley et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin Fragment P1," FEBS Letters 291(1):50-54 (1991).
Fauchere et al., "Modulation of the Activity and Assessment of the Receptor Selectivity in a Series of New RGD-containing Peptides," Int'l J. Peptide & Protein Res. 42(5):440-444 (1993).
PCT Search Report (dated 9 Nov. 1995), International application No. PCT/US95/04741.
Ross, R. Patrick et al., "Interactions Between the Bone Matrix Proteins Osteopontin and Bone Sialoprotein and the Osteoclast Integrin .alpha..sub.V .beta..sub.3 Potentiate Bone Resorption." J. Biol. Chem. 268:9901-9907 (1993).
Chuntharapai Anan et al., "Blocking Monoclonal Antibodies to .alpha..sub.V .beta..sub.3 Integrin: A Unique Epitope of .alpha..sub.V .beta..sub.3 Integrin is Present on Human Osteoclasts." Experimental Cell Res. 205:345-352 (1993).
Helfrich, Miep H. et al., "Rat Osteoclasts Adhere to a Wide Range of RGD (Arg-Gly-Asp) Peptide-Containing Proteins, Including the Bone Sialoproteins and Fibronectin, via a .beta..sub.3 Integrin." J. Bone and Mineral Res. 7:335-343 (1992).
Miyauchi, Akimitsu et al., "Recognition of Osteopontin and Related Peptides by an .alpha..sub.V .beta..sub.3 Integrin Stimulates Immediate Cell Signals in Osteoclasts." J. Biol. Chem. 266:20369-20374 (1991).
Choi, Eric T. et al., "Inhibition of Neointimal Hyperplasia by Blocking .alpha..sub.V .beta..sub.3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA." J. Vascular Surg. 19:125-134 (1994).
Horton, M.A. et al., "Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23c6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts." Experimental Cell Res. 195:368-375 (1991).
Brooks, Peter C. et al., "Requirement of Vascular Integrin .alpha..sub.V .beta..sub.3 for Angiogenesis." Science 264:569-571 (1994).
Denis, Cecile et al., "Solid-Phase von Willebrand Factor Contains a Conformationally Active RGD Motif that Mediates Endothelial Cell Adhesion Through the .alpha..sub.V .beta..sub.3 Receptor." Blood 82:3622-3630 (1993).
Brooks, Peter C. et al., "Integrin .alpha..sub.V .beta..sub.3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels." Cell 79:1157-1164 (1994).
Matsuno, Hiroyuki et al., "Inhibition of Integrin Function by a Cyclic RGD-Containing Peptide Prevents Neointuma Formation." Circulation 90:2203-2206 (1994).
Hayashi, Kimiiko et al., "Endothelial Cells Interact with the Core Protein of Basement Membrane Perlecan Through .beta.1 and .beta.3 Integrins: An Adhesion Modulated by Glycosaminoglycan." J. Cell Biol. 119:945-959 (1992).
Pfaff, Martin et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by .alpha.IIb.beta.3, .alpha.V.beta.3, and .alpha.5.beta.3, and .alpha.5.sym.1 Integrins." J. Biol. Chem. 269:20233-20238 (1994).
Endocrinology, vol. 132, No. 3, issued Mar. 1993, Fisher et al, "Inhibition of Osteoclastic Bone Resorption . . . ", pp. 1411-1413.
J. Biol. Chem., vol. 263, issued 25 Dec. 1988, Gan et al, "Echistatin", pp. 19827-19832.

Affiliated with

Also associated with

Rating

Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1859310